Owlstone Medical secures $6.5 million to support development of breath-based diagnostics for infectious disease Post author: Post published:April 25, 2024 Post category:uncategorized Funding represents the first time the foundation has taken an equity position in a breath diagnostics company. You Might Also Like BIOHIT introduces the FAEX™ Sample System for stool sample collection and handling February 26, 2025 Surprising study reveals dads’ weight and diet don’t impact baby’s size March 4, 2025 Pheno Therapeutics receives clinical trial authorization for novel multiple sclerosis therapeutic January 15, 2025
Pheno Therapeutics receives clinical trial authorization for novel multiple sclerosis therapeutic January 15, 2025